Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
11:51:50 EDT Thu 25 Apr 2024
Enter Symbol
or Name
USA
CA



News for U:GRFS from 2023-04-26 to 2024-04-25 - 15 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-04-19 16:42U:GRFSNews ReleaseGrifols 2023 Annual Report on Form 20-F filed with the SEC
2024-04-18 09:30U:GRFSNews ReleaseGrifols Celebrates 50 Years of Manufacturing Life-Changing Plasma-Derived Medicines for Patients at Flagship Site in Clayton, N.C.
2024-04-04 04:00U:GRFSNews ReleaseGrifols Procleix ArboPlex Assay(TM) Receives CE Mark, the First and Only 4-in-1 NAT for Arbovirus Screening
2024-02-14 03:17U:GRFSNews ReleaseGrifols announces positive topline phase 3 fibrinogen clinical trial results
2024-01-20 11:04U:GRFSNews ReleaseROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Grifols, S.A. Investors to Inquire About Securities Class Action Investigation - GRFS, GIKLY, GIFOF, GIFLF
2023-11-15 08:00U:GRFSNews ReleaseGrifols Completes Cohort 1 in Clinical Study of Alpha-1 15%, Evaluating First-in-Human Subcutaneous Dosing Option for Patients with Alpha1-Antitrypsin Deficiency
2023-11-06 08:00U:GRFSNews ReleaseGigaGen Presents IND-Enabling Data and Phase 1 Trial Strategy for its Novel Anti-CTLA-4 Oncology Drug Candidate, GIGA-564, at SITC 2023
2023-10-24 18:31U:GRFSNews ReleaseAraclon Biotech Presents Positive Final Results from Phase 2 Clinical Study of ABvac40 Alzheimer ¢ € ™s Vaccine at CTAD
2023-10-19 08:00U:GRFSNews ReleaseGigaGen Granted Expansion of Contract with US Department of Defense to Develop Synthetic Human Antibody Treatments for Botulinum Neurotoxins
2023-09-28 08:00U:GRFSNews ReleaseGigaGen Partners with the National Cancer Institute to Advance Oncology Drug Candidate GIGA-564
2023-08-01 08:00U:GRFSNews ReleaseGrifols Accelerates Healthcare Innovation with Google Cloud ¢ € ™s AI and Analytics
2023-07-20 08:15U:GRFSNews ReleaseGrifols Achieves Positive Topline Results From Phase 4 Study of XEMBIFY ‚ ® (immune globulin subcutaneous human-klhw) Evaluating Biweekly Dosing Option for Patients
2023-07-18 08:00U:GRFSNews ReleaseGrifols Completes Enrollment in Phase 3 Study of Long-term Albutein ‚ ® (albumin-human injection) Therapy for Patients with Decompensated Cirrhosis
2023-07-13 08:00U:GRFSNews ReleaseGrifols Meets Enrollment Target in Phase 3 Study of Two Dose Regimens of Prolastin ‚ ®-C in Patients with Emphysema Due to Alpha-1-Antitrypsin Deficiency
2023-05-11 08:30U:GRFSNews ReleaseGrifols Launches AlphaID ¢ „ ¢ At Home, Enabling U.S. Consumers to Self-Screen for Genetic COPD